HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Inc.

www.exelixis.com

Latest From Exelixis Inc.

BMS Sales Surged In Q1 Even Without Big COVID-19 Boost

Bristol Myers Squibb brought in $500m from customers that overbought in case of drug shortages, but first quarter sales still grew 8% excluding those purchases and BMS projects growth through 2021.

Sales & Earnings Business Strategies

Opdivo/Cabometyx Combo ‘Very Encouraging' In 1L RCC

Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.

ImmunoOncology Clinical Trials

NICE Rejects Keytruda/Inlyta Combo First-Line In RCC

The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.

Cancer Health Technology Assessment

BMS Earnings Beat Estimates, But Opdivo Sales Slide Continues

The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.

Sales & Earnings ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exelixis Inc.
  • Senior Management
  • Michael M Morrissey, PhD, Pres. & CEO
    Christopher J Senner, EVP, CFO
    Peter Lamb, PhD, EVP, Scientific Strategy & CSO
    Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
    Dana T Aftab, PhD, EVP, Bus. Operations
  • Contact Info
  • Exelixis Inc.
    Phone: (650) 837-7000
    1851 Harbor Bay Parkway
    Alameda, CA 94502
    USA
UsernamePublicRestriction

Register